This retrospective, multivariable study was designed to compare transplant outcomes among pediatric patients with hematological malignancies receiving T-cell depletion haploidentical transplant using CD3+/CD19+ or TCRαβ+/CD19+ platforms. This evidence concerns the gene CD19 and hematologic disorder.